Georgina Long, PhD, MBBS, FRACP, University of Sydney, Sydney, Australia, talks on adjuvant targeted therapies for patients with melanoma, highlighting five-year results of dabrafenib combined with trametinib versus placebo in resected stage III melanoma (NCT01584648). Five-year results are consistent with three-year results, reporting a relapse-free survival benefit with a risk reduction of 50%. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.